Braendle W
Division of Gynecological Endocrinology and Reproductive Medicine, University Hospital, Hamburg-Eppendorf, Germany.
Anticancer Res. 1998 May-Jun;18(3C):2253-5.
The influence of estrogens on the growth of mammary carcinoma cell lines has been confirmed by many studies. Therefore, past or recent history of breast cancer is principally seen as a contraindication for estrogen or estrogen/progestin replacement therapy. The recently made possible early diagnosis of mammary carcinomas in many cases has resulted in a better prognosis, and means that following treatment women are living for a long time postmenopausally. Therefore, hormone replacement therapy is demanded by many patients. Recent studies with a limited number of patients, however, have shown no adverse effects of an estrogen or an estrogen-progestin replacement therapy after treatment of a mammary carcinoma. In some studies even a positive effect has been found in recurrence free survival. However, a final decision upon estrogen or estrogen/progestin replacement therapy in postmenopausal women with a history of breast cancer, cannot be made until the results of prospective clinical trials are finalized.
许多研究已证实雌激素对乳腺癌细胞系生长的影响。因此，乳腺癌的既往史或近期病史主要被视为雌激素或雌激素/孕激素替代疗法的禁忌证。近年来，在许多病例中能够实现乳腺癌的早期诊断，从而带来了更好的预后，这意味着接受治疗后的女性在绝经后能够长期生存。因此，许多患者都需要激素替代疗法。然而，近期针对少数患者的研究表明，乳腺癌治疗后进行雌激素或雌激素 - 孕激素替代疗法并无不良影响。在一些研究中，甚至发现对无复发生存有积极作用。然而，在关于前瞻性临床试验结果确定之前，无法对有乳腺癌病史的绝经后女性是否进行雌激素或雌激素/孕激素替代疗法做出最终决定。
